- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01817270
Immunogenicity and Safety Study of 2 Doses of Live Attenuated Varicella Vaccine
October 14, 2013 updated by: Changchun Keygen Biological Products Co., Ltd.
A Study to Evaluate the Immunogenicity and Safety of 2 Doses of Live Attenuated Varicella Vaccine
The purpose of this study is to observe the occurrence of adverse events, seroconversion rate and geometric mean titres(GMTs) of 2 doses of live attenuated varicella vaccine.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
368
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Guangdong
-
Yunfu, Guangdong, China
- Xinxing Center for Disease Control and Prevention
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 3 years (Child)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Parent/legal acceptable representative is willing and able to understand the protocol requirements and provide informed consent
- Participant is aged ≥ 1 year to ≤ 3 years
- Participant without preventive inoculation of varicella vaccine and previous history of chickenpox and zoster
- Subject and parent/guardian able to attend all scheduled visits and comply with all trial procedures
- Body temperature ≤ 37.5℃
Exclusion Criteria:
- Known allergy to any constituent of the vaccine
- Known acute illness, severe chronic disease, acute exacerbation of chronic disease and fever
- Known or suspected impairment of immunologic function, or receipt of immunosuppressive therapy or immunoglobulin since birth
- Reported the history of allergies, convulsions, epilepsy, mental illness and brain disease and clear serious systemic reaction
- Failed to the Expanded Programme on Immunization(EPI)
- Receipt of any vaccine in the 4 weeks preceding the trial vaccination
- Plan to receive any vaccine in the 4 weeks following the trial vaccination
- Known bleeding disorder
- Receipt of whole blood, blood plasma or immunoglobulin in the 5 months preceding the trial vaccination
- Reported the history of acute illness had need systemic antibiotics or anti-viral treatment of infections in the 7 days preceding the trial vaccination
- An acute illness with or without fever (temperature ≥ 38.0℃) in the 3 days preceding enrollment in the trial
- Participation in any other interventional clinical trial
- Any condition which, in the opinion of the investigator, would pose a health risk to the subject or interfere with the vaccine
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Live Attenuated Varicella Vaccine
use the left arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Seroconversion rate and GMTs for live attenuated varicella vaccine
Time Frame: 35-42 days after the first and second doses
|
35-42 days after the first and second doses
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Occurrence of adverse events
Time Frame: within 30 days after each vaccination
|
within 30 days after each vaccination
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Huizhen Zheng, Master, Guangdong Center for Disease Prevention and Control
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2013
Primary Completion (Actual)
August 1, 2013
Study Completion (Actual)
August 1, 2013
Study Registration Dates
First Submitted
March 4, 2013
First Submitted That Met QC Criteria
March 20, 2013
First Posted (Estimate)
March 25, 2013
Study Record Updates
Last Update Posted (Estimate)
October 16, 2013
Last Update Submitted That Met QC Criteria
October 14, 2013
Last Verified
October 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NCT02038506
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chickenpox
-
GlaxoSmithKlineLudwig-Maximilians - University of MunichCompletedVaricella (Chickenpox) | Chickenpox VaccinesGermany
-
GlaxoSmithKlineCompletedVaricella | Chickenpox VaccinesRussian Federation, Romania, Czechia, Slovakia, Italy, Sweden, Poland, Greece, Norway, Lithuania
-
Changchun Changsheng Life Science and Technology...Guangdong Provincial Institute of Biological Products And Materia MedicaUnknown
-
Merck Sharp & Dohme LLCCompleted
-
Zhuhai Trinomab Pharmaceutical Co., Ltd.Not yet recruiting
-
GlaxoSmithKlineCompleted
-
Merck Sharp & Dohme LLCCompleted
-
GlaxoSmithKlineIQVIA, USAActive, not recruitingChickenpoxTaiwan, Poland, United States, Estonia, Puerto Rico, Mexico
-
Karo Pharma ABCompleted
-
Merck Sharp & Dohme LLCCompletedVaricellaRussian Federation
Clinical Trials on Live Attenuated Varicella Vaccine
-
Changchun Keygen Biological Products Co., Ltd.Guangdong Provincial Institute of Biological Products And Materia MedicaCompletedJapanese Encephalitis | ChickenpoxChina
-
China National Biotec Group Company LimitedBeijing Institute of Biological Products Co Ltd.; Jiangsu Province Center for...Active, not recruiting
-
Zhejiang Provincial Center for Disease Control...Changchun Keygen Biological Products Co., Ltd.Completed
-
China National Biotec Group Company LimitedBeijing Institute of Biological Products Co Ltd.; Jiangsu Province Center for...Active, not recruiting
-
Sinovac (Dalian) Vaccine Technology Co., Ltd.Completed
-
Sinovac (Dalian) Vaccine Technology Co., Ltd.Recruiting
-
Sinovac (Dalian) Vaccine Technology Co., Ltd.Active, not recruiting
-
Sinovac (Dalian) Vaccine Technology Co., Ltd.Completed
-
Sanofi Pasteur, a Sanofi CompanyCompleted
-
National Institute of Allergy and Infectious Diseases...Merck Sharp & Dohme LLC; Cooperative Clinical Trials in Pediatric Transplantation and other collaboratorsTerminatedKidney Transplant RecipientsUnited States